🎉 M&A multiples are live!
Check it out!

Structure Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Structure Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Structure Therapeutics Overview

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.


Founded

2019

HQ

United States of America
Employees

163

Website

structuretx.com

Financials

LTM Revenue $14.4M

LTM EBITDA -$168M

EV

$207M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Structure Therapeutics Financials

Structure Therapeutics has a last 12-month revenue of $14.4M and a last 12-month EBITDA of -$168M.

In the most recent fiscal year, Structure Therapeutics achieved revenue of n/a and an EBITDA of -$157M.

Structure Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Structure Therapeutics valuation multiples based on analyst estimates

Structure Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$102M -$157M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$51.3M -$89.6M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Structure Therapeutics Stock Performance

As of April 15, 2025, Structure Therapeutics's stock price is $19.

Structure Therapeutics has current market cap of $1.1B, and EV of $207M.

See Structure Therapeutics trading valuation data

Structure Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$207M $1.1B XXX XXX XXX XXX $-0.79

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Structure Therapeutics Valuation Multiples

As of April 15, 2025, Structure Therapeutics has market cap of $1.1B and EV of $207M.

Structure Therapeutics's trades at 14.4x LTM EV/Revenue multiple, and -1.2x LTM EBITDA.

Analysts estimate Structure Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Structure Therapeutics and 10K+ public comps

Structure Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $207M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -1.3x XXX XXX XXX
P/E -8.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Structure Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Structure Therapeutics Valuation Multiples

Structure Therapeutics's NTM/LTM revenue growth is 148%

Structure Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.0M for the same period.

Over next 12 months, Structure Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Structure Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Structure Therapeutics and other 10K+ public comps

Structure Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 53% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Structure Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Structure Therapeutics M&A and Investment Activity

Structure Therapeutics acquired  XXX companies to date.

Last acquisition by Structure Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Structure Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Structure Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Structure Therapeutics

When was Structure Therapeutics founded? Structure Therapeutics was founded in 2019.
Where is Structure Therapeutics headquartered? Structure Therapeutics is headquartered in United States of America.
How many employees does Structure Therapeutics have? As of today, Structure Therapeutics has 163 employees.
Who is the CEO of Structure Therapeutics? Structure Therapeutics's CEO is Professor Raymond C. Stevens, PhD.
Is Structure Therapeutics publicy listed? Yes, Structure Therapeutics is a public company listed on NAS.
What is the stock symbol of Structure Therapeutics? Structure Therapeutics trades under GPCR ticker.
When did Structure Therapeutics go public? Structure Therapeutics went public in 2023.
Who are competitors of Structure Therapeutics? Similar companies to Structure Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Structure Therapeutics? Structure Therapeutics's current market cap is $1.1B
What is the current revenue of Structure Therapeutics? Structure Therapeutics's last 12-month revenue is $14.4M.
What is the current EBITDA of Structure Therapeutics? Structure Therapeutics's last 12-month EBITDA is -$168M.
What is the current EV/Revenue multiple of Structure Therapeutics? Current revenue multiple of Structure Therapeutics is 14.4x.
What is the current EV/EBITDA multiple of Structure Therapeutics? Current EBITDA multiple of Structure Therapeutics is -1.2x.
Is Structure Therapeutics profitable? Yes, Structure Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.